David Giddings

dg

Senior business advisor focused on the life sciences and information technology industries. Proven expertise and success in dealing with turnaround, start-up and/or distressed firms; developing and executing liquidity event strategies; forming and implementing strategic partnerships, fund raising and marketing for high value, tech-intensive firms, especially in early growth stages.

Mr. Giddings’ business career has focused on IT, healthcare and life science companies, where he served in senior management positions with both established and emerging public and private companies. For over two decades he held general management positions for Eastman Kodak’s Commercial Imaging, Business Services and Healthcare Groups, including VP and General Manager of Clinical Diagnostics; Printing and Publishing,; and Business Imaging Systems Divisions.

In 1991 he joined Boehringer Mannheim Corporation, a leading global pharmaceutical and life science firm, as VP and GM for the Diagnostics Division, and subsequently became BMC’s President and COO. In 1995 he was appointed Chairman and CEO of Diametrics Medical, a NASDAQ traded company, and held this position for six years.

Mr. Giddings joined Digilab LLC as President and one of its three shareholders in 2001. Proceeds from the sale of significant Digilab assets to Varian, Inc. in 2004 were used by Digilab to become a “C Corp” in 2006, focusing on advanced technologies and solutions for life sciences. Digilab made several acquisitions and partnered with leading firms in the global research “tools” market. Its platforms and products include genomics, proteomics, and liquid handling and imaging instrument-based systems acquired from Harvard Biosciences in late 2007. Mr. Giddings served as Digilab’s CEO and President until 2009 and remains an active shareholder in the company.

Mr. Giddings has served on multiple boards, including ACCPAC, a wholly owned subsidiary of Computer Associates; Gentra Systems Inc., sold to Qiagen with Mr. Giddings leading the Board initiative to facilitate the transaction; Heartsine Inc., a global leader in AED and arterial fibrillation technology; and Liposcience Inc., a leader in advanced cardiovascular diagnostic services and products. He is currently a board member of Axela Inc., a market leader in instrumentation and consumables for multiplexed MDX tests; and of Allotrope Pharmaceuticals, where he also serves as interim CEO. Allotrope’s platform technology, Anchor Enzyme Complex, focuses on the treatment of biofilm based infectious diseases, with dental plaque as its first target.

Mr. Giddings has a BA degree from Middlebury College; an MBA from Rider University; and completed Harvard’s 3-month Advanced Management Program.